Curium US to Acquire Lantheus in a $8 Billion Deal

Curium entered a merger agreement on August 3, 2026, to acquire Lantheus Holdings, Inc. (LNTH) in a deal valued at $8 billion.

Deal Structure:

Curium US will acquire all of the outstanding shares of Lantheus for $102.5 per share in cash at closing, representing a premium of 2.87% from the stock’s last close.

The shareholders will also receive non-transferable Contingent Value Rights (CVRs) providing for up to $12 per share in potential additional cash payments, subject to achievement of specified commercial milestones for Lantheus’ products through 2030.

Company Profile:

Lantheus is a pharmaceutical company that develops, manufactures, and commercializes diagnostic imaging agents and radiopharmaceuticals for the diagnosis and treatment of cancer, cardiovascular disease, and other conditions. The company supplies its products to hospitals, radiopharmacies, imaging centers, and healthcare providers worldwide.

Curium is a radiopharmaceutical company that develops, manufactures, and supplies diagnostic and therapeutic radiopharmaceuticals for the diagnosis and treatment of cancer. The company operates globally, with a portfolio of nuclear medicine products and a pipeline focused on oncology.

Deal Details and Timeline:

In May, Bloomberg reported that Lantheus was weighing a sale after getting a takeover offer from Curium. The stock was trading at $94.47 when it was revealed that Curium was valuing the radiopharma company at about $7 billion.

The transaction is expected to be financed through a mix of debt and equity.

The merger is expected to close in the first half of 2027.

Lantheus was advised by Morgan Stanley, BofA Securities, and Solomon Partners on financial matters, and by Covington & Burling and Ropes & Gray on legal matters. Curium US was advised by Jefferies, J.P. Morgan Securities, and PJT Partners on financial matters, and by Kirkland & Ellis and Arnold & Porter Kaye Scholer on legal matters.

Curium is purchasing Lantheus at 18.06 times EBITDA.

Deal Metrics:

For an in-depth understanding of this M&A deal, you can visit the Deal Metrics page at this link:

Deal Metrics for the acquisition of Lantheus Holdings, Inc. (LNTH) by Curium US Holdings LLC

The Deal Metrics page offers comprehensive information on each merger or acquisition, including:

• A spread history chart of the merger from announcement through completion or failure.
• Progression of the merger through the HSR period, regulatory approvals, shareholder votes, and more.
• News and SEC filings related to the merger.
• A history of deal updates.
• And a plethora of additional information.

Disclaimer: This article is intended for informational purposes only. Please conduct your own due diligence before buying or selling any securities mentioned in this article. We do not guarantee the completeness or accuracy of the content or data provided in this article.